ACET:NSD-Adicet Bio Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 12.92

Change

-0.23 (-1.75)%

Market Cap

USD 0.57B

Volume

0.25M

Avg Analyst Target

USD 32.25 (+149.61%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Adicet Bio Inc (ACET) Stock Analysis:
Based on the Adicet Bio Inc stock forecasts from 4 analysts, the average analyst target price for Adicet Bio Inc is USD 32.25 over the next 12 months. Adicet Bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adicet Bio Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Adicet Bio Inc’s stock price was USD 12.92. Adicet Bio Inc’s stock price has changed by -2.00% over the past week, -2.93% over the past month and -10.53% over the last year.

About

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumo ...Read More

Company Website : https://www.adicetbio.com

Address : 500 Boylston Street, Boston, MA, United States, 02116

Employees : 81

Fiscal Year End : June

Currency: USD

Country : USA

Technical Indicators

Beta : 2.01

52 Week High : 18.49

Short Ratio : 0.31

52 Week Low : 6.25

Shorted Shares : 909,913

200 Day Moving Average : 10.65

Shorted Shares Previous Month : 1,079,341

50 Day Moving Average : 13.03

Shares Held By Insiders : 11.42%

Short Percentage : 4.35%

Shares Held by Institutions : 60.94%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

 USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

 USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

 USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

 USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

 USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

 USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

 USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

 USD17.76B N/A N/A

ETFs Containing ACET

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.13% 15% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.13% 15% F 8% F
Trailing 12 Months  
Capital Gain -10.53% 84% B 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.53% 84% B 44% F
Trailing 5 Years  
Capital Gain -34.58% 49% F 20% F
Dividend Return 1.75% 25% F 4% F
Total Return -32.84% 49% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain 2,187.23% 99% A+ 99% A+
Dividend Return 0.45% 25% F 13% F
Total Return 2,187.69% 99% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 4,033.17% 1% F 1% F
Risk Adjusted Return 54.24% 84% B 74% C
Market Capitalization 0.57B 70% C- 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.60 21% F 24% F
Price/Book Ratio 2.04 67% D+ 56% F
Price / Cash Flow Ratio -13.72 74% C 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -33.01% 75% C 34% F
Return on Invested Capital -147.09% 8% F 4% F
Return on Assets -14.06% 78% C+ 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.31 93% A 88% B+
Short Percent 4.35% 50% F 36% F
Beta 2.01 14% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector